Tadalafil is NOT indicated for treating COPD
Tadalafil should not be used for the treatment of chronic obstructive pulmonary disease (COPD), including COPD with secondary pulmonary hypertension. The most authoritative guideline evidence explicitly states that drugs approved for primary pulmonary hypertension are not recommended for patients with pulmonary hypertension secondary to COPD 1. Earlier guidelines similarly concluded there is no evidence that pulmonary vasodilators have any role in patients with COPD and pulmonary hypertension 2.
Why Tadalafil Fails in COPD
The rationale against using tadalafil (a phosphodiesterase-5 inhibitor) in COPD is supported by high-quality research evidence:
The definitive trial evidence shows no benefit: A 2014 randomized, double-blind, placebo-controlled trial in 120 patients with moderate-to-severe COPD and mild pulmonary hypertension found that tadalafil 10 mg daily for 12 weeks produced no improvement in 6-minute walk distance (difference of only 0.5 meters, p=0.937) and no improvement in quality of life measures 3. This study directly contradicts any theoretical benefit of pulmonary vasodilation in this population.
The most recent trial confirms these findings: A 2022 multicenter VA study of 42 veterans with COPD-PH using tadalafil 40 mg daily for 12 months showed no significant difference in 6-minute walk distance (the primary endpoint) and no improvement in pulmonary vascular resistance or mean pulmonary artery pressure at 6 months 4. While a secondary endpoint showed improvement in shortness of breath scores, this was insufficient to change the overall negative conclusion, particularly given the study's under-enrollment issues.
Standard COPD Treatment Algorithm
The evidence-based approach to COPD management does not include tadalafil at any stage 1:
For symptomatic patients with low exacerbation risk (Group B):
- Start with a single long-acting bronchodilator (LABA or LAMA)
- If persistent breathlessness occurs, escalate to dual bronchodilator therapy (LABA/LAMA)
For high-risk patients with frequent exacerbations (Group D):
- Initiate LABA/LAMA combination as first-line therapy
- If exacerbations persist, escalate to triple therapy (LABA/LAMA/ICS)
- If still exacerbating on triple therapy, consider adding roflumilast (for FEV1 <50% with chronic bronchitis) or macrolide therapy (in former smokers with appropriate screening)
Critical Safety Concerns
The FDA labeling for tadalafil does not include COPD as an approved indication 5. The drug carries significant cardiovascular risks including:
- Hypotension and vasodilatory effects that may be problematic in COPD patients with cardiovascular comorbidities
- Contraindication with nitrates (commonly used in COPD patients with coronary disease)
- Risk of drug interactions with common COPD medications
Common adverse effects from the COPD trials included dyspepsia (32% vs 8% placebo), headache (28% vs 8%), and facial flushing 3, making the risk-benefit ratio clearly unfavorable given the lack of efficacy.
The Bottom Line
Pulmonary hypertension secondary to COPD represents a fundamentally different pathophysiology than primary pulmonary arterial hypertension. The pulmonary vascular changes in COPD are driven by chronic hypoxia, inflammation, and structural lung disease—mechanisms not adequately addressed by PDE-5 inhibition. Focus treatment on evidence-based bronchodilators, appropriate use of inhaled corticosteroids based on exacerbation history and blood eosinophil counts, supplemental oxygen for hypoxemia, and pulmonary rehabilitation 1.